SEC Form 4 · accession 0001193125-26-382456

CORCEPT THERAPEUTICS INC · CORT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Roberto Wandenkolk Vieira

Officer — President, Oncology

Period of report

Sep 1, 2026

Accepted (ET)

Sep 3, 2026 · 9:02 pm EDT

Rule 10b5-1 plan

yes — trade under a plan

Issuer CIK

0001088856

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2,F3	Sep 1, 2026	A	138	$113.38	A	4,206	D
Common Stock^F4,F3	Sep 1, 2026	A	138	$0.00	A	4,344	D
Common Stock^F6,F7	Sep 2, 2026	F	102	$113.38	D	4,242	D
Common Stock^F7	Sep 2, 2026	M	58,333	$21.63	A	62,575	D
Common Stock^F9,F7	Sep 2, 2026	S	23,600	$109.3506	D	38,975	D
Common Stock^F10,F7	Sep 2, 2026	S	23,770	$110.7004	D	15,205	D
Common Stock^F11,F7	Sep 2, 2026	S	1,537	$111.3733	D	13,668	D
Common Stock^F12,F7	Sep 2, 2026	S	974	$112.3966	D	12,694	D
Common Stock^F13,F7	Sep 2, 2026	S	1,606	$113.7187	D	11,088	D
Common Stock^F14,F7	Sep 2, 2026	S	5,621	$114.5779	D	5,467	D
Common Stock^F15,F7	Sep 2, 2026	S	1,225	$115.4395	D	4,242	D

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F16	$21.63	Sep 2, 2026	M	58,333	D	—	Feb 1, 2034	Common Stock	58,333	141,667	D

Explanation of responses

F1The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
F10Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F11Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F12Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F13Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F14Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F15Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F16Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable ratably on a monthly basis over a period of 36 consecutive months thereafter until fully vested and exercisable on January 29, 2028, subject to the Reporting Person's continued service.
F2In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F5These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
F6The closing price on September 1, 2026 was used to calculate the withholding obligation.
F7Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F8This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the time of this transaction.
F9Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Remarks

The power of attorney under which this form was signed is on file with the Commission.